Equita Adds DiaSorin to Small Cap Portfolio with 'Buy' Rating

Equita has added DiaSorin (DIA) to its small-cap portfolio and upgraded its rating to 'buy' ahead of the company's upcoming quarterly earnings report. This decision indicates a positive outlook on DiaSorin's financial performance, reflecting growing investor interest as the company approaches its next disclosure period.